Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback